1. Home
  2. NOA vs MLYS Comparison

NOA vs MLYS Comparison

Compare NOA & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NOA
  • MLYS
  • Stock Information
  • Founded
  • NOA 1953
  • MLYS 2019
  • Country
  • NOA Canada
  • MLYS United States
  • Employees
  • NOA N/A
  • MLYS N/A
  • Industry
  • NOA Meat/Poultry/Fish
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • NOA Consumer Staples
  • MLYS Health Care
  • Exchange
  • NOA Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • NOA 556.4M
  • MLYS 634.6M
  • IPO Year
  • NOA 2006
  • MLYS 2023
  • Fundamental
  • Price
  • NOA $20.49
  • MLYS $9.24
  • Analyst Decision
  • NOA
  • MLYS Strong Buy
  • Analyst Count
  • NOA 0
  • MLYS 2
  • Target Price
  • NOA N/A
  • MLYS $30.00
  • AVG Volume (30 Days)
  • NOA 49.4K
  • MLYS 266.6K
  • Earning Date
  • NOA 03-12-2025
  • MLYS 11-11-2024
  • Dividend Yield
  • NOA 1.67%
  • MLYS N/A
  • EPS Growth
  • NOA N/A
  • MLYS N/A
  • EPS
  • NOA 1.41
  • MLYS N/A
  • Revenue
  • NOA $874,213,701.00
  • MLYS N/A
  • Revenue This Year
  • NOA $25.68
  • MLYS N/A
  • Revenue Next Year
  • NOA $8.31
  • MLYS N/A
  • P/E Ratio
  • NOA $13.07
  • MLYS N/A
  • Revenue Growth
  • NOA 35.78
  • MLYS N/A
  • 52 Week Low
  • NOA $16.46
  • MLYS $8.28
  • 52 Week High
  • NOA $25.92
  • MLYS $16.91
  • Technical
  • Relative Strength Index (RSI)
  • NOA 45.61
  • MLYS 32.12
  • Support Level
  • NOA $20.21
  • MLYS $8.60
  • Resistance Level
  • NOA $21.22
  • MLYS $9.97
  • Average True Range (ATR)
  • NOA 0.58
  • MLYS 0.88
  • MACD
  • NOA -0.13
  • MLYS -0.31
  • Stochastic Oscillator
  • NOA 23.19
  • MLYS 13.25

About NOA North American Construction Group Ltd. (no par)

North American Construction Group Ltd is Canada's heavy civil construction and mining contractor provider. The company has provided services to oil, natural gas, and resource companies. The Company provides a wide range of mining and heavy civil construction services to customer in the resource development and industrial construction sectors within Canada, the United States, and Australia. The Company's reportable segments are Heavy Equipment - Canada, Heavy Equipment - Australia, and Other. Heavy Equipment - Canada and Heavy Equipment - Australia include all of aspects of the mining and heavy civil construction services provided within those geographic areas. Other includes our mine management contract work in the United States, its external maintenance and rebuild programs.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

Share on Social Networks: